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Abstract
Background: Cancer cachexia is a multifactorial metabolic syndrome characterized by marked loss of adipose tissue
and skeletal muscle. Fat loss from adipose tissue in cancer cachexia is partly the result of increased lipolysis. Despite
the growing amount of studies focused on elucidating the mechanisms through which lipolysis-related proteins
regulate the lipolytic process, there are scarce data concerning that profile in the adipose tissue of cancer cachectic
patients. Considering its fundamental importance, it was our main purpose to characterize the expression of the
lipolysis-related proteins in the white adipose tissue of cachectic cancer patients.
Methods: Patients from the University Hospital were divided into three groups: control, cancer cachexia (CC), and
weight-stable cancer patients (WSC). To gain greater insight into adipose tissue wasting during cancer cachexia
progression, we have also analyzed an experimental model of cachexia (Walker 256 carcinosarcoma). Animals were
divided into: control, intermediate cachexia (IC) and terminal cachexia (TC). Subcutaneous white adipose tissue of
patients and epidydimal white adipose tissue of animals were investigated regarding molecular aspects by
determining the protein content and gene expression of hormone-sensitive lipase (HSL), adipose triglyceride lipase
(ATGL), comparative gene identification-58 (CGI-58), perilipin 1, leptin, adiponectin, visfatin, and tumour necrosis
factor alpha (TNF-alpha).
Results: We found augmented lipolysis in CC associated with increased HSL expression, as well as upregulation of
ATGL expression and reduction in perilipin 1 content. In IC, there was an imbalance in the secretion of pro- and
anti-inflammatory factors. The alterations at the end-stage of cachexia were even more profound, and there was a
reduction in the expression of almost all proteins analyzed in the animals.
Conclusions: Our findings show that cachexia induces important morphological, molecular, and humoral
alterations in the white adipose tissue, which are specific to the stage of the syndrome.
Background
Adipose tissue is the body’s largest energy reservoir and
a major source of metabolic fuel. In addition to its pri-
mary role, white adipose tissue has been affirmed as a
major endocrine organ, since the tissue synthesizes and
secretes an array of hormones and proteins, the adipo-
kines [1]. These adipokines allow an extensive cross talk
among adipose tissue and other organs, including the
brain, the liver, and the skeletal muscle.
Cancer cachexia is a multifactorial metabolic syndrome
characterized by marked loss of adipose tissue and skeletal
muscle, which cannot be fully reversed by conventional
nutritional support and leads to progressive functional im-
pairment [2]. While muscle wasting is associated with
shorter survival time and is clearly linked with reduced
quality of life, depletion of fat is also a prognostic marker
for poor outcome [3].
Fat loss from adipose tissue in cancer cachexia is partly
the result of increased lipolysis [4–9]. Initially, hormone-
sensitive lipase (HSL) was thought to be the rate-limiting
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enzyme of the first lipolytic step, while we now know that
adipocyte triglyceride lipase (ATGL) is the key enzyme for
lipolysis initiation. HSL mRNA and protein levels are in-
creased in the adipose tissue of patients with cancer cach-
exia [10–12], and studies have shown increased ATGL
expression in the adipose tissue of cachectic animals [11,
13]. Moreover, ATGL-deficient mice with tumors resisted
increased white adipose tissue lipolysis and maintained
normal adipose and gastrocnemius muscle mass [9].
Pivotal components have also been identified at the
protective interface of the lipid droplet surface and in the
signaling pathways that control lipolysis. Perilipin,
comparative gene identification-58 (CGI-58), and other
proteins of the lipid droplet surface are currently known
to be key regulators of the lipolytic machinery, protecting
or exposing the TAG core of the droplet to lipases [14].
Despite growing amount of studies focused on elucidating
the mechanisms through which all these lipolysis-related
proteins regulate the lipolytic process, there are scarce data
concerning that profile in the adipose tissue of cancer cach-
ectic patients. Considering its fundamental importance, it
was our main purpose to characterize the expression of the
lipolysis-related proteins in the subcutaneous white adipose
tissue of cachectic cancer patients. To gain greater insight
into adipose tissue wasting during cancer cachexia progres-
sion, we have also analyzed an experimental model of cach-
exia. Determination of some adipokines that may be
involved in cachexia progression was also performed. We
describe for the first time significant alteration in the protein
expression of ATGL in the subcutaneous white adipose tis-
sue of cachectic cancer patients.
Methods
Experimental design
Patients and sample collection
Patients were recruited between November 2008 and July
2010 at University Hospital of the University of São Paulo.
The inclusion criteria were as follows: 1, not having re-
ceived prior anticancer treatment and 2, willingness to par-
ticipate. The exclusion criteria were as follows:
chemotherapy at the time of the study; continuous anti-
inflammatory therapy; and kidney or liver failure, acquired
immunodeficiency syndrome, inflammatory bowel disease
or chronic inflammatory processes not related with cach-
exia, such as autoimmune disorders. Patients with body
mass index (BMI) greater than 29.9 kg/m2 were also
excluded from the study. The study was approved by the
Ethics Committee from the Institute of Biomedical
Sciences and by the Human Ethics Committee of the
University of São Paulo Hospital (CEP-ICB/USP 1117/13,
CEP-HU/USP 752/07 and 1117/13, CAAE 0031.0.198.019–
07). The investigation was explained in detail to each pa-
tients, and written informed consent was obtained. They
were separated into three groups, based on diagnosis after
surgery. The subjects were subdivided into cancer cachexia
(CC, n = 17), weight-stable cancer (WSC, n = 10) and
weight-stable control (non-cancer) (control, n = 7). Patients
were considered cachectic based on criteria from inter-
national consensus [15]. Cachexia is recognized in patients
with weight loss >5% in the past 6 months or any degree of
weight loss >2% in the last 6 months + BMI < 20 kg/m2.
The weight stable groups were considered as those with no
important weight change during the previous year and
BMI < 25 kg/m2. In the cancer groups (CC and WSC) the
tumour primary location was colon, stomach, pancreas and
other. The control group included patients undergoing sur-
gery for incisional hernia and chronic cholecystitis, condi-
tions which do not present chronic inflammation.
Approximately 10 mL of blood was collected after over-
night fast, within the venous access procedure for anaes-
thesia during the surgery. Blood was collected into tubes
containing EDTA and plasma samples were obtained after
centrifugation (3000 rpm for 15 min at 4 oC). Plasma was
stored at −80 °C for posterior analysis. Approximately 1 g
of subcutaneous white adipose tissue was collected in
within a 5 min interval, similarly to that described by
Agustsson et al. [8]. The adipose tissue biopsy was
immediately transferred into liquid nitrogen and kept
at −80 oC before analysis. This procedure presents a
minimal degree of risk and does not interfere with
the surgery procedure.
Experimental cachexia model
Male adult Wistar rats (180–200 g), obtained from the
Institute of Biomedical Sciences, University of São Paulo,
were maintained in a 12 h light:12 h darkness cycle,
under controlled temperature conditions (22 ± 2 °C) and
relative humidity at 60%, receiving water and food
(NUVILAB 1, Nuvital, Brazil) ad libitum. The Ethical
Committee for Animal Research from the Institute of
Biomedical Sciences, University of São Paulo, approved
all the adopted procedures (Protocol no. 041/2005),
which were carried out in accordance with the Brazilian
College for Animal Experimentation (COBEA).
Weight and food intake were assessed three times per
week, always in the afternoon. To characterise different
stages of cachexia progression, animals were randomly
assigned into three experimental groups: control,
tumour-bearing sacrificed on the seventh day (inter-
mediate cachexia - IC) and tumour-bearing sacrificed on
the fourteenth day (terminal cachexia - TC) after tumour
inoculation. Walker 256 tumour cells (2 × 107 cells)
were injected subcutaneously into the right flank of the
rats [16]. Control animals received saline injections on
the same day of tumour inoculation. The experimental
procedures were carried out on the seventh (IC group)
and fourteenth days (control and TC groups) following
tumour inoculation.
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Real time PCR
Total RNA was obtained from aliquots of 300 mg of
subcutaneous or epidydimal white adipose tissue by Tri-
zol® reagent (Invitrogen, USA) extraction according to
the manufacture’s recommendations. The first strand of
cDNA was generated from 2 μg of total RNA, employing
a commercial kit (High Capacity cDNA Reverse Tran-
scription Kit, Invitrogen). Polymerase chain reaction
(PCR) amplification was performed in duplicates, with
SYBR Green PCR Master Mix (Applied Biosystems, CA,
USA) in the QuantStudio™ 12 K Flex Real Time PCR
(Applied Biosystems, CA, USA), employing the primers
listed in Table 1. Gene expression was normalized to
18S (humans) or GAPDH (rats). Data were calculated
with the 2-ΔΔCT method and are presented as the fold
change in gene expression relative to the control sample.
Protein analysis by Western blotting
The white adipose tissue was homogenised in 1.0 mL
solubilisation buffer at 4 °C (1% Triton X-100, 100 mM
Tris-HCl (pH 7.4), 100 mM sodium pyrophosphate, 100
mM sodium fluoride, 10 mM EDTA, 10mM sodium
orthovanadate, 2.0 mM phenylmethylsulphonyl fluoride
(PMSF), and 0.1 mg aprotinin/mL) with a Polytron
(model 713 T; Fisatom Equipamentos Científicos, São
Paulo, SP, Brazil). Insoluble material was removed by
centrifugation for 30 min at 9000 g in a 70.Ti rotor
(Beckman, Fullerton, CA, USA) at 4 °C. The protein
concentration of the supernatants was measured by the
BCA assay. Proteins were denatured by boiling (5 min)
in Laemmli sample buffer containing 100 mM DTT, run
on 8, 10, or 12% SDS-PAGE gel in a Bio-Rad miniature
slab gel apparatus. The electrotransfer of proteins from
gels to nitrocellulose membranes was performed for
~1.30 h/4 gels at 15 V (constant) in a Bio-Rad semidry
transfer apparatus. Nonspecific protein binding to the
nitrocellulose was reduced by preincubation for 2 h at
22 °C in blocking buffer (1% bovine serum albumine, 10
mM Tris, 150mM NaCl, and 0.02% Tween 20). The
nitrocellulose membranes were incubated overnight at
4 °C with antibodies against HSL, ATGL, CGI-58, perili-
pin 1, and alpha-tubulin (Santa Cruz Biotechnology, CA,
USA) diluted 1: 1000 with blocking buffer supplemented
with 1% BSA and then washed for 30 min in blocking
buffer without BSA. The blots were subsequently incu-
bated with peroxidase-conjugated secondary antibody
for 1 h at 22 °C. For evaluation of protein loading, mem-
branes were stripped and reblotted with an anti-alpha-
tubulin antibody as appropriate. Specific bands were de-
tected by chemiluminescence, and visualization/capture
was performed by exposure of the membranes to RX
films. Band intensities were quantified by optical densi-
tometry of developed autoradiographs (Scion Image
software-Scion Corporation, Frederick, MD, USA).
Plasma determinations
Glucose, free fatty acids, triacilglycerol, HDL-cholesterol
and total cholesterol plasma concentration was deter-
mined using commercial enzymatic kits (Labtest®, São
Paulo, Brazil). LDL cholesterol was calculated according
to Friedewald et al. Leptin and insulin plasma levels
were measured by radioimmunoassay (Linco Research
Inc. and Siemens, respectively). Adiponectin and visfatin
plasma concentration was assessed by ELISA (Invitro-
gen,United States).
Adipokine tissue concentration
The adipose tissue was homogenised and centrifuged at
12,000 g for 40 min at 4 °C; the supernatant was saved,
and the protein concentration was determined using the
BCA assay (Bio-Rad, Hercules, California) with bovine
serum albumin (BSA) as a reference. Quantitative assess-
ment of adiponectin, visfatin and TNF-alpha tissue pro-
teins was carried out by ELISA (DuoSet ELISA, R and D
Systems, Minneapolis, MN) and the concentration of
leptin was carried out by radioimmunoassay (Linco Rea-
search, United States). All samples were assayed as du-
plicates, and the mean value was reported. Results were
equalised to total protein.
Morphological analysis
Samples of the epididymal white adipose tissue were
fixed in 4% paraformaldehyde, pH 7.4 for 24 h at 4oC,
followed by dehydration in increasing ethanol solutions
concentration (70, 95, 100%), cleared in xylene and then,
embedded in paraffin. The sequential 5 μm sections ob-
tained were stained with haematoxylin and eosin. Tissue
images were obtained with a ×40 objective lens, re-
corded on a digital camera (DFC 295, Leica), displayed
on a high resolution monitor (LG, Flatron, E1941). Mor-
phometric aspects, area, average diameter, perimeter and
shape were analysed and measured by Image Pro-Plus
6.0 (100 adipocytes per stained section).
Statistical analysis
The statistical analysis was performed using the software
SigmaStat (version 3.1, SigmaStat, SYSTAT, Point Rich-
mond, CA). Data are expressed are as mean ± s.e.m. and
analysed by one-way analysis of variance. When a sig-
nificant F-value was found by one-way analysis of vari-
ance, a Bonferroni’s post hoc test was performed to
demonstrate all pairwise multiple comparisons between
the means. A P < 0.05 was considered significant.
Results
Clinical findings
Baseline characteristics of the patients are shown in Table 2.
All the groups were matched for age and body mass index
(BMI). However, the CC patients showed considerably
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drastic body weight loss (about 5.0-fold compared to WSC,
p < 0.05). Free fatty acids concentration was also markedly
augmented in CC when compared with control (2.6-fold,
p < 0.05). It is notable that both cancer groups showed dys-
lipidemia. Total-cholesterol was higher in CC and WSC
relative to control (1.5-fold and 1.6-fold, respectively,
p < 0.05). Similarly, there was an increased concentration of
LDL-C in CC (2.3-fold) and WSC (1.9-fold), both p < 0.05.
WSC also presented higher VLDL concentration when
compared with CC (21%, p < 0.05). Results for IL-6, IL-10,
TNF-alpha, adiponectin, leptin and resistin have been pub-
lished previously [17].
Adipokines gene expression
Table 3 shows mRNA levels of leptin, adiponectin and
visfatin in the subcutaneous white adipose tissue of pa-
tients. Adiponectin gene expression was almost 5.0-fold
higher in CC when compared with control (p < 0.05). In
the same way, mRNA levels of visfatin were significantly
higher in CC (18-fold and 5.0-fold relative to control
and WSC, respectively). Leptin gene expression was
higher in WSC when compared with CC (p < 0.05).
Gene and protein expression of lipolysis-related proteins
The gene expression of HSL, ATGL, CGI-58 and
perilipin-1 are showed in Fig. 1a. As expected, the gene
expression of HSL in CC was higher than control
(p < 0.05). On the other hand, there was no alteration in
ATGL mRNA levels. However, gene expression of CGI-
58, the ATGL co-activator, was increased in CC when
compared with control patients (p < 0.05). Perilipin-1
gene expression was higher in WSC when compared
with other groups (p < 0.05).
Similarly to HSL mRNA levels, the protein content of
this enzyme was increased in CC when compared to
control (p < 0.05) (Fig. 1b). It was also observed a higher
protein content of ATGL in CC relative to control
(p < 0.05). The perilipin-1 protein content was signifi-
cantly decreased in CC when compared to control
(p < 0.05).
Experimental findings
Characterization of cachexia syndrome
Walker 256 is a well-established experimental model of
cancer cachexia inducing most of the syndrome-
correlated symptoms that are reported for cancer pa-
tients, as weight loss, fat depletion and decrease of food
intake [18, 19]. In agreement with previous reports, body
weight was decreased (after tumour tissue weight was
subtracted) in tumour-bearing animals. Body weight gain
was 77.2 ± 6.1 g in control animals and 20.0 ± 6.1 g in
IC (p < 0.05 related to other groups). Nevertheless, TC
presented an important weight loss (28.6 ± 12.0 g) dur-
ing the experimental period (p < 0.05 when compared
with other groups). Anorexia, an important signal of
cachexia, was evident in tumour-bearing rats. Food in-
take was reduced in IC by 38% and in TC by 54%, when
compared with control (p < 0.05). This reduction was
significant from the fifth day after tumour inoculation
and remained until the end of the experimental period
(data not shown).
Cancer cachexia had significant effect on relative
weight (percentage of total body weight) of epididymal
and retroperitoneal white adipose tissue. Both depots
were reduced in IC and TC compared with control rats.
However, no differences were found regarding relative
weight of mesenteric adipose tissue, nor upon liver and
Table 2 Characteristics of study groups
Control CC WSC
n
Gender (male/female)
20
11–9
17
10–7
10
4–6
Age (years) 51.1 ± 3.6 58.4 ± 4.0 66.9 ± 4.3
BMI (kg/m2) 23.3 ± 0.9 20.6 ± 0.8 22.9 ± 0.7
Weight loss (%) 1.9 ± 1.0 19.9 ± 1.9a,b 4.0 ± 0.5
Staging, n (%)
IA 0 (0) 3 (30.0)
IB 0 (0) 0 (0)
IIA 0 (0) 0 (0)
IIB 2 (11.7) 1 (10.0)
IIIA 4 (23.5) 1 (10.0)
IIIB 2 (11.7) 1 (10.0)
IV 9 (53.0) 4 (40.0)
CRP (mg/dL) 9.5 ± 6.8 92.3 ± 15.4b 90.4 ± 31.2b
Haemoglobin (g/dL) 12.4 ± 0.5 11.4 ± 0.4 11.3 ± 0.6
Urea (mg/dL) 36.9 ± 2.7 35.3 ± 6.5 36.9 ± 3.5
Free fatty acids (μM) 680.9 ± 30.1 1786.9 ± 551.0b 917.3 ± 43.3
Glucose (mM) 5.51 ± 0.2 5.3 ± 0.2 6.01 ± 0.4
Insulin (ng/mL) 0.5 ± 0.1 0.3 ± 0.1 0.6 ± 0.1
Cholesterol (mg/dL) 183.9 ± 13.7 287.3 ± 65.2b 300.0 ± 54.1b
HDL(mg/dL) 52.8 ± 3.3 42.8 ± 7.0 64.1 ± 9.9
VLDL (mg/dL) 29.5 ± 1.5 28.5 ± 0.6a 36.4 ± 3.0
LDL (mg/dL) 104.0 ± 11.6 239.8 ± 54.1b 200.3 ± 42.4b
Triacylglycerol (mg/dL) 147.8 ± 9.2 142.6 ± 3.8 182.1 ± 17.9
CC cancer cachexia, WSC weight-stable cancer
Values are mean ± s.d. aP < 0.001 versus WSC. bP < 0.05 versus Control
Table 3 Adipokines gene expression in the subcutaneous white
adipose tissue of patients
Control CC WSC
Leptin (arbitrary units) 1.00 ± 0.47 0.17 ± 0.08 2.72 ± 0.81b
Visfatin (arbitrary units) 1.00 ± 0.27 18.85 ± 1.40a 3.74 ± 1.34b
Adiponectin (arbitrary units) 1.00 ± 0.15 4.71 ± 1.17a 3.08 ± 0.78,
CC cancer cachexia, WSC weight-stable cancer
Values are mean ± s.e.m. n = 7–12 per group.aP < 0.05 versus
Control.bP < 0.05 versus CC
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muscle weight. The relative weight of tumour was 3.7-
fold higher in TC (3.2 ± 1.2%) when compared with IC
(12.0 ± 1.9%) (p < 0.05).
Plasma measurements
As illustrated by Table 4, the adiponectin and visfatin
plasma concentration was diminished in TC (p < 0.05
when compared with control and IC). Plasma leptin levels
were decreased in IC and TC (p < 0.05 vs. control). Plasma
free fatty acids and triacylglycerol concentrations were in-
creased in terminal cachexia (TC) when compared with
control and IC groups.
Morphological aspects and morphometrical analysis
We examined whether the dramatic reduction in adipose
tissue was apparent at the microscopic level. Haematoxy-
lin/Eosin staining revealed important alterations between
the epididymal white adipose tissue of control and cachec-
tic animals. Adipocyte size was dramatically reduced in IC
and TC when compared with control (p < 0.05) (Fig. 2).
Moreover, tissue analysis showed cell size variation in IC
(Fig. 2b) and shrunken and polygonal adipocytes in TC
(Fig. 2c). Marked changes in the extracellular matrix were
also observed in terminal cachexia, suggesting impairment
of cellular function.
Gene and protein expression of adipokines
The reduction in the epididymal white adipose tissue
weight was accompanied by drastic changes in gene and
protein expression of adipokines (Table 5). In the middle-
stage of cachexia (IC) there was a reduction in leptin gene
expression and an increase in adiponectin and visfatin
mRNA levels (Table 5). At the end-stage of the syndrome
(TC) there was a great reduction of adiponectin mRNA,
and visfatin gene expression returned to control values,
while leptin showed even lower mRNA levels (Table 5). In
addition, we also evaluate the protein expression of leptin,
adiponectin, visfatin and TNF-alpha (Table 5). There was
a decrease in leptin and adiponectin tissue content in IC
(P < 0.05 vs. control). At the end-stage of cachexia (TC)
Fig. 1 Lipolysis-related proteins expression in subcutaneous white adipose tissue from patients. CC cancer cachexia, WSC weight-stable cancer, HSL
hormone-sensitive lipase, ATGL adipose triglyceride lipase, CGI-58 comparative gene identification-58. a Gene expression of HSL, ATGL, perilipin 1 and
CGI-58. mRNA levels of target genes were normalized to 18 S, n = 7–12 per group. b Protein expression of HSL, ATGL and perilipin1, n = 8 per
group. Values are mean ± s.e.m. * P < 0.05 versus Control, # P < 0.05 versus CC
Table 4 Plasma measurements of experimental groups
Control IC TC
n
Adiponectin (ng/mL)
6
20.6 ± 1.4
7
19.4 ± 2.9
9
7.7 ± 0.9a,b
Leptin (ng/mL) 2.5 ± 0.1 1.1 ± 0.2a 0.7 ± 0.3 a
Visfatin (ng/mL) 68.1 ± 5.8 80.2 ± 7.8 33.0 ± 6.6 a,b
Insulin (ng/mL) 1.0 ± 0.0 0.6 ± 0.2 0.5 ± 0.2
Glucose (mg/dL) 100.1 ± 4.2 96.7 ± 5.3 105.1 ± 6.3
Free fatty acids (μM) 629.6 ± 94.5 758.9 ± 37.0 1423.8 ± 66.5 a,b
Triacylglycerol (mg/dL) 64.9 ± 8.4 124.1 ± 26.4 236.4 ± 36.5 a,b
IC intermediate cachexia, TC terminal cachexia
Values are mean ± s.e.m.aP < 0.05 versus Control.bP < 0.05 versus IC
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the response was different: the leptin tissue concentration
was maintained and adiponectin showed an even more
pronounced decrease (P < 0.001 vs. control and IC). The
TNF-alpha tissue concentration was 2.0-fold higher in IC
(P < 0.05 vs. control) and 2.5-fold higher in TC (P < 0.05 vs.
control and IC). Moreover, the adiponectin concentration
was inversely correlated with the TNF-alpha level in the epi-
didymal white adipose tissue (r = − 0.80, P = 0.003) (Fig. 3).
Gene and protein expression of proteins involved in lipolysis
To examine the contribution of lipases to mobilization of
triacylglycerol, the gene and protein expression of HSL,
ATGL, CGI-58 and perilipin 1 was carried out in the epi-
didymal white adipose tissue (Fig. 4). The HSL gene ex-
pression was higher in IC, while other proteins were
unaffected. At the end-stage of cachexia (TC), the HSL
gene expression was similar to control values and the
other proteins mRNA levels were reduced. However, pro-
tein expression showed a different pattern: ATGL and
CGI-58 were reduced, while perilipin 1 presented a ten-
dency for reduction (P = 0.06 vs. control) in TC.
Discussion
Clinical studies documenting enhanced lipolysis in cachec-
tic cancer patients implicate lipases such as ATGL and
HSL in the development of cachexia [9]. Our results show,
for the first time, profound changes in ATGL and perilipin-
1 protein expression in the subcutaneous white adipose
tissue of cachectic cancer patients. Moreover, the CGI-58
modulation during cancer cachexia has never been shown
before.
Lipolysis is tightly regulated through ATGL and HSL,
of which ATGL is the initial rate-limiting enzyme in the
conversion of triacylglycerol into glycerol and free fatty
Fig. 2 Morphological characteristics and morphometric analysis of epidydimal white adipose tissue during cachexia progression. IC intermediate
cachexia, TC terminal cachexia. Morphometric analysis of cell surface area, diameter and perimeter of adipocytes from different experimental
groups. (a) Control, (b) intermediate cachexia, (c) terminal cachexia. Note adipocytes of various sizes from IC and shrunken and shapeless
adipocytes in TC. Values are mean ± s.e.m. * P < 0.05 versus control; # P < 0.05 versus IC
Table 5 Adipokines gene and protein expression in the epidydimal white adipose tissue from animals
Control IC TC
Gene expression
Leptin (arbitrary units) 1.00 ± 0.08 0.57 ± 0.11a 0.15 ± 0.08a,b
Visfatin (arbitrary units) 1.00 ± 0.18 5.1 ± 1.63a 1.17 ± 0.32b
Adiponectin (arbitrary units) 1.00 ± 0.14 3.68 ± 0.26a 0.18 ± 0.09,a,b
Protein expression
Leptin (ng.mg of protein−1) 3.57 ± 0.53 1.91 ± 0.34a 1.50 ± 0.16a
Visfatin (ng.mg of protein−1) 27.55 ± 2.59 31.66 ± 2.83 12.67 ± 5.54,a,b
Adiponectin (mg.mg of protein−1) 0.21 ± 0.01 0.14 ± 0.01a 0.09 ± 0.01a,b
TNF-alpha (pg.μg of protein−1) 23.86 ± 2.87 44.52 ± 2.88a 57.61 ± 3.33a,b
IC intermediate cachexia, TC terminal cachexia
Values are mean ± s.e.m. n = 8–12 per group. aP < 0.05 versus Control. bP < 0.05 versus IC
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acids [20]. In agreement with previous reports, we ob-
served a great increase in HSL gene and protein expression
in the subcutaneous white adipose tissue in cancer cach-
exia. However, studies have shown that while HSL makes
some contribution to enhanced lipolysis in cancer cachexia,
ATGL-mediated lipolysis of triglycerides appears to pre-
dominate [9, 13]. The absence of ATGL and, to a lesser
degree, HSL reduces fatty acids mobilization, retains white
adipose tissue and muscle mass, and prevents cancer cach-
exia [9]. Consistent with these data, we showed for the first
time an increased ATGL protein content in the subcutane-
ous white adipose tissue of cancer cachectic patients. ATGL
activity is regulated through interaction with its co-
regulator CGI-58, but in the basal state CGI-58 is seques-
tered in a complex with perilipin 1 [20]. Downregulation of
perilipin due to chronic TNF-alpha treatment correlates
with stimulation of lipolysis [2, 21]. Thus, the higher CGI-
58 mRNA level concomitant with the reduced perilipin 1
content in the subcutaneous white adipose tissue of cachec-
tic patients strongly confirm the crucial role of ATGL in
the lipolytic process in such condition.
Studies of lipid metabolism in cachexia have generally
focused on later stages of the disorder when severe loss
of adipose tissue has already occurred. Therefore, we
also studied adipose tissue in the Walker-256 carcinosar-
coma model to identify the contribution of these
lipolysis-related proteins to the fat mass loss during
cachexia progression. In contrast to the aforementioned
results, in cachectic cancer animals we detected an in-
crease in the mRNA level of HSL only during the middle
of the experimental period (IC), without any variation in
HSL protein content. Interestingly, the ATGL mRNA
and protein levels were markedly reduced at the end-
stage of the syndrome (TC), as well as CGI-58
expression.
Fig. 3 Correlation between TNF-alpha and adiponectin levels in the
epidydimal white adipose tissue from animals. n = 8–12 per group.
Values are mean ± s.e.m.
Fig. 4 Lipolysis-related proteins expression in epidydimal white adipose tissue during cancer cachexia progression. HSL hormone-sensitive lipase,
ATGL adipose triglyceride lipase, CGI-58 comparative gene identification-58, IC intermediate cachexia, TC terminal cachexia. a Gene expression of HSL,
ATGL, perilipin 1 and CGI-58. mRNA levels of target genes were normalized to GAPDH, n = 6–12 per group. b Protein expression of HSL, ATGL,
perilipin 1 and CGI-58, n = 6–9 per group. Values are mean ± s.e.m. * P < 0.05 versus Control, # P < 0.05 versus IC
Silvério et al. Lipids in Health and Disease  (2017) 16:159 Page 8 of 11
Recently our study group demonstrated an important
structural modification in the subcutaneous white adi-
pose tissue of cachectic patients, including remodeling
of the extra-cellular matrix, increased collagen amounts,
adipocyte size reduction, and adipose tissue atrophy
[22]. Some aspects of this structural modification of the
white adipose tissue were also observed in our experi-
mental model. Evidence indicates that adipose tissue re-
modeling in obesity is closely associated with adipose
tissue function [23]. Changes in the number and size of
the adipocytes affect the microenvironment of expanded
fat tissues, accompanied by alterations in adipocyte
death, local hypoxia, and adipokine secretion [24].
Adipokines play a role in a wide variety of physio-
logical or pathological processes, including immunity
and inflammation, in addition to having significant ef-
fects on metabolism. The association between cancer
cachexia and adipokine level alterations has been re-
ported [17, 25, 26]. Increased production of lipolytic fac-
tors by the adipose tissue, such as TNF-alpha,
contributes to the disrupted lipid metabolism and in-
creased lipolysis in cancer cachexia [2, 8]. Thereby, the
white adipose tissue is both a victim and a sponsor of
cachexia-related systemic inflammation [7, 27].
Leptin has a pivotal role in the control of food intake,
and there are controversial results on leptin and cancer
cachexia in literature [19, 26, 28, 29]. We found a re-
duced leptin plasma level as well as mRNA and protein
content in the epididymal white adipose tissue of cach-
ectic animals. Previously, our study group also showed a
decrease in leptin plasma level and mRNA content in
the subcutaneous white adipose tissue of cancer cachetic
patients [17]. It has been shown that pro-inflammatory
cytokines, such as IL-1beta and TNF-alpha, decrease
leptin gene and protein expression in adipocytes from
subcutaneous white adipose tissue of humans [30]. This
interaction might influence the circulating leptin levels
and thereby the adipose tissue to brain signaling.
Insulin resistance is an early event in cachexia devel-
opment and may be a role in cachexia pathogenesis [11].
According to literature, high plasma levels of leptin are
related to insulin resistance, and leptin reduces insulin
sensitivity in isolated adipocytes [31]. Therefore, it seems
paradoxical that a positive association between low
serum leptin levels and insulin resistance was found in
cancer patients [32].
A recent study showed that insulin treatment prevented
the increased expression of ATGL and HSL in the retroperi-
toneal white adipose tissue, as well as increased the food in-
take of tumor-bearing rats [11]. Visfatin (nicotinamide
phosphoribosyltransferase – NAMPT) was described as an
insulin-mimetic adipokine secreted from visceral fat [33]. We
demonstrated a marked increase on visfatin gene expression
in white adipose tissue in experimental intermediate cachexia
(IC), and the same was observed in the subcutaneous white
adipose tissue of cancer cachexia patients. Visfatin can im-
prove insulin sensitivity [34], and we therefore hypothesize
that this increase may be an attempt to compensate the insu-
lin insensitivity observed in cachexia syndrome. However, its
plasma and protein levels in white adipose tissue were not
upregulated in these animals and patients. Moreover, animals
at the end-stage of the syndrome (TC) showed reduced visfa-
tin plasma levels as well as mRNA and protein content in
white adipose tissue.
Adiponectin is another adipose-specific protein that is
important to regulate insulin resistance and has a potent
anti-inflammatory function. It circulates in high concen-
tration in the plasma, and its levels are reported to be in-
versely correlated with body weight. Nevertheless, the role
of this adipokine in the setting of cancer cachexia is con-
troversial. We showed higher adiponectin plasma levels in
cachectic cancer patients [17], as well as other study
groups [26, 35]. However, inconsistent results show low
adiponectin levels [25, 36], or even absence of correlation
in cachexia patients [37]. The higher mRNA content in
subcutaneous white adipose tissue of CC is consistent
with our previous report [17]. Opposite results were found
in experimental cancer cachexia. Using the experimental
model, we showed that adiponectin levels increased in the
fourth day after tumor inoculation and, subsequently, that
Fig. 5 Changes along cachexia progression
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level decreased (similar to cachectic cancer patients). This
increase may represent a compensatory response aimed at
controlling the syndrome progression.
The pro-inflammatory cytokine TNF-alpha, which is syn-
thesized in both adipocytes and infiltrated macrophages
[38], regulates the function and development of white adi-
pose tissue by stimulating lipolysis and inhibiting lipogen-
esis and adipogenesis [39]. Furthermore, TNF-alpha has
regulatory functions on adiponectin in the human visceral
white adipose tissue, and TNF-alpha levels are elevated in
states of insulin resistance [40]. We verified a progressive
increase on TNF-alpha protein content in the visceral white
adipose tissue of cachectic rats. Besides, there was a nega-
tive correlation between adiponectin and TNF-alpha levels
in the visceral white adipose tissue of these animals. These
data indicate a modulation of the chronically and locally
produced TNF-alpha upon adiponectin synthesis by the
white adipose tissue of cachectic animals.
Conclusions
Despite potential species-specific (human vs. rat) and
depot-specific (subcutaneous vs. visceral) response, it is
possible to infer that the data from cancer cachectic
patients are similar to intermediate cachexia. Moreover,
we hypothesize that the alterations in terminal cachexia
animals are consistent to the alterations observed in
patients with refractory cachexia.
The main findings of this study are integrating in Fig. 5.
In summary, we found augmented lipolysis in cachectic
patients associated with increased ATGL and HSL protein
expression, as well as reduction in perilipin 1. On the
intermediate stage of the syndrome, similar to the clinical
study, there was an imbalance in the secretion of pro- and
anti-inflammatory factors. At this stage, it seems that the
modulation of adipokines gene expression is an attempt to
unsuccessfully preserve fat mass. The alterations at the
end-stage of cachexia were even more profound, and the
marked decrease in adipokine and lipolysis-related protein
expression, associated with changes in the extracellular
matrix and adipocyte shape, suggests impairment of cellu-
lar function in terminal cachexia. Our findings show that
cachexia induces important morphological, molecular and
humoral alterations in the white adipose tissue, which are
specific to the stage of the syndrome.
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